Note: There were 2 supplements to Volume 28. The March/April supplement was produced by American Journal of Nursing and is listed separately in the index. Page numbers preceded by S indicate the May/June supplement.
A
Acromegaly, 36
ACTH, deficiency/excess of, 36
Acute lung injury, furosemide for, serum epidermal growth factor concentration after, 188
Alanine aminotransferase, increased, causes of, 108
Albumin, decreased, causes of, 108
Alcoholic liver disease, liver function tests in, 108
Alkaline phosphatase, increased, causes of, 108
Allergic reactions
to blood products, universal leukocyte reduction for, 273
to caboplatin, 170
to IV immunoglobulin, 265
to paclitaxel, 170
Alloimmunization, universal leukocyte reduction for, 273
Alternative and complementary therapy, liver function tests in, 108
Aminotransferase, increased, causes of, 108
Anabolic steroids, liver function tests for, 108
Analgesia, in juvenile idiopathic arthritis, 385
Anorexia nervosa, electrolyte imbalances in, outpatient management of, 118
Antidiuretic hormone, deficiency/excess of, 36
Antimicrobial resistance, 183
Antineoplastic therapy, allergic reactions in, 170
Antiseptics
combination povidone iodine-alcohol, 314
safety and effectiveness of, 194
Arginine vasopressin, deficiency/excess of, 36
Arthritis, juvenile idiopathic, 385
Aseptic meningitis, after IV immunoglobulin infusion, 265
Asthma, acute exacerbations in, magnesium sulfate for, 329
Autoimmune hepatitis, liver function tests in, 108
B
Bicarbonate imbalance, in eating disorders, 118
Blindness, in juvenile idiopathic arthritis, 385
Blood products, universal leukocyte reduction for, 273
Blood sampling, through peripherally inserted central catheter devices, in children, 30
Bortezomib, for multiple myeloma, 258
Bulimia nervosa, electrolyte imbalances in, outpatient management of, 118
C
Cancer
chemotherapy for, allergic reaction to, 170
proteasome inhibition for, 258
Carboplatin, allergic reaction to, 170
Caregiver teaching, for home infusion therapy, 99
Catheter(s), S7
access devices for. See Vascular access devices
central venous. See Central venous catheters
epidural, management of, 377
intrathecal, management of, 377
peripheral intravenous, flushing of, frequency of, 399
plasticizers in, safety of, in neonates, 54
Central venous catheters
access devices for. See Vascular access devices
innovations in, S7
patients' experience with, 61
peripherally inserted
blood sampling through, in children, 30
full-time specialist staff for, 45
insertion of, nurse training in, S7
occlusion of, nurse training in, 173
placement of, innovations in, S7
Chemotherapy, allergic reactions in, 170
Children. See also Neonates
asthma exacerbations in, magnesium sulfate for, 329
blood sampling in, through peripherally inserted central catheter devices, 30
juvenile idiopathic arthritis in, 385
Chloride imbalances, in eating disorders, 118
Chronic liver disease, liver function tests in, 108
Combination povidone iodine-alcohol formulations, 314
Community-wide infusion therapy programs, development and implementation of, 307
Complementary therapy, liver function tests in, 108
Computerized patient data, privacy of, 251
Confidentiality, of electronic patient data, 251
Congestive heart failure
end-stage, home care for, 393
liver function tests in, 108
Continuing education credits. See CRNI(R) Certification Examination
Cost containment, S22
CRNI(R) Certification Examination, review questions for, 68, 405, S33
Cytomegalovirus infection, transfusion-related, 273
Cytotoxic drugs
allergic reactions to, 170
D
Dehydration, hypodermoclysis for, 123
Di-2-ethylhexylphthalate plasticizer, safety of, in neonates, 54
Diabetes insipidus, 36
Diagnostic tests, affecting vascular devices, S13
Drug abuse
liver function tests in, 108
in pregnancy, neonatal abstinence syndrome and, 159
Drug reactions
to carboplatin, 170
to IV immunoglobulin, 265
to paclitaxel, 170
Drug therapy
antimicrobial resistance in, 183
hepatotoxicity in, liver function tests and, 108
safety of. See Medication safety
E
Eating disorders, electrolyte imbalances in, outpatient management of, 118
Editorials, 8, 85, 148, 218, 299, 359
Education
nurse, for peripherally inserted central catheters
for insertion and management, S7
for occlusion management and prevention, 173
patient/family
health literacy and, 15
for home infusion therapy, 99
Elderly, hypodermoclysis in, 123
Electrolyte imbalances
in eating disorders, outpatient management of, 118
in refeeding syndrome, 337
Electronic patient data, privacy of, 251
End-stage heart failure, home care in, 393
Enterocolitis, neonatal necrotizing, 130
Epidermal growth factor concentration, after furosemide infusion, for acute lung injury, 188
Epidural catheters, management of, 377
Epidurograms, 377
F
Family teaching, for home infusion therapy, 99
Fluid management
hypodermoclysis in, 123
in refeeding syndrome, 337
Flushing, of peripheral intravenous catheters, frequency of, 399
Follicle-stimulating hormone, deficiency/excess of, 36
Furosemide, for acute lung injury, serum epidermal growth factor concentration after, 188
G
Gamma-glutamyltransferase, increased, causes of, 108
Growth hormone, deficiency/excess of, 36
H
Health literacy, patient teaching and, 15
Heart failure
end-stage, home care in, 393
liver function tests in, 108
Hepatobiliary disease, liver function tests in, 108
Herbal remedies, liver function tests in, 108
Home infusion therapy
in end-stage heart failure, 393
patient/family teaching for, 99
Hyperbilirubinemia, liver function tests in, 108
Hyperchloremia, in eating disorders, 118
Hypernatremia, in eating disorders, 118
Hyperprolactinemia, 36
Hypochloremia, in eating disorders, 118
Hypodermoclysis, 123
Hypokalemia, in eating disorders, 118
Hyponatremia, in eating disorders, 118
Hypoprolactinemia, 36
I
IgG anaphylaxis, after IV immunoglobulin infusion, 265
Immunoglobulin. See Intravenous immunoglobulin
Infants. See Children; Neonates
Infusion Nurses Society
2004 Financial Report, 237
Chief Executive Officer's Report, 240
Presidential Address, 248
State of the Society Report, 231
Infusion systems
"smart," 321
Infusion therapy
community-wide programs for, development and implementation of, 307
cost containment in, S22
home-administered
in end-stage heart failure, 393
patient/family teaching for, 99
legal issues in, S18
Intrathecal catheters, management of, 377
Intravenous immunoglobulin
administration of, practice guidelines for, 265
selection of, 366
J
Juvenile idiopathic arthritis, 385
L
Lactate dehydrogenase, increased, causes of, 108
Leukocyte reduction, universal, 273
Liability issues, S18
Liver function tests, 108
in eating disorders, 118
Lung injury, acute, furosemide for, serum epidermal growth factor concentration after, 188
Luteinizing hormone, deficiency/excess of, 36
M
Macrophage activation syndrome, in juvenile idiopathic arthritis, 385
Magnesium sulfate, for asthma exacerbations, 329
Malnutrition, refeeding syndrome in, 337
Malpractice, nursing, S18
Medical records, electronic, privacy of, 251
Medicare reimbursement issues, S22
Medication(s)
allergic reactions to, 170, 265
antimicrobial resistance to, 183
hepatotoxic, liver function tests and, 108
Medication safety
administration, March/April supplement
in ambulatory infusion setting, 170
smart infusion systems and, 321
symposium on, 87
Meningitis, aseptic, after IV immunoglobulin infusion, 265
Methicillin-resistant Staphylococcus aureus, 183
Microintroducers, S7
Modified Seldinger technique, S7
Multiple myeloma, bortezomib for, 258
N
Necrotizing enterocolitis, neonatal, 130
Negligence, by infusion nurse, S18
Neonatal abstinence syndrome, 159
Neonatal necrotizing enterocolitis, 130
Neonates. See also Children
di-2-ethylhexylphthalate exposure in, 54
New products and services, 72, 135, 208, 282, 343, 409
Nonalcoholic steatohepatitis, liver function tests in, 108
Nurse education, for peripherally inserted central catheters
for insertion and management, S7
for occlusion management and prevention, 173
Nursing malpractice, S18
Nutritional support, refeeding syndrome and, 337
O
Occlusion
of peripherally inserted central catheters
management and prevention of, 173
Oxytocin, deficiency/excess of, 36
P
Paclitaxel, allergic reactions to, 170
Pain management, in juvenile idiopathic arthritis, 385
Patient records, electronic, privacy of, 251
Patient/family teaching
health literacy and, 15
for home infusion therapy, 99
Pediatric patients. See Children; Neonates
Peripheral intravenous catheters. See also Catheter(s)
flushing of, frequency of, 399
Peripheral neuropathy, bortezomib-related, 258
Peripherally inserted central catheters. See also Catheter(s)
blood sampling through, in children, 30
full-time specialist staff for, 45
occlusion of, nurse training in, 173
patient's experience with, 61
placement of
innovations in, S7
nurse training in, S7
Pituitary disorders, 36
Plasticizers, safety of, in neonates, 54
Ports
diagnostic tools and therapeutic interventions affecting, S13
for epidural catheters, 377
innovations in, S7
for intrathecal catheters, 377
legal aspects of, S18
patients' experience with, 61
Potassium imbalances, in eating disorders, 118
Povidone iodine-alcohol formulations, 314
Precertification, infusion nurse's role in, 23
Privacy, of electronic patient data, 251
Prolactin, deficiency/excess of, 36
Proteasome inhibitors, for multiple myeloma, 258
Prothrombin time, in hepatobiliary disease, 108
Q
Quality of life, venous access ports and, 61
R
Refeeding syndrome, 337
Rehydration, hypodermoclysis in, 123
Reimbursement issues, S22
Renal failure, after IV immunoglobulin infusion, 265
S
Safety. See Medication safety
State of the Science on Safe Medication Administration, March/April supplement
Seldinger technique, S7
Serum epidermal growth factor concentration, after furosemide infusion, for acute lung injury, 188
Smart infusion systems, 321
Sodium imbalances, in eating disorders, 118
Staphylococcus aureus, methicillin-resistant, 183
Steatohepatitis, nonalcoholic, liver function tests in, 108
Steroids, anabolic, liver function tests for, 108
Substance abuse
liver function tests in, 108
in pregnancy, neonatal abstinence syndrome and, 159
Syndrome of inappropriate antidiuretic hormone secretion, 36
T
Terminal care, in-home, in congestive heart failure, 393
Therapeutic interventions, affecting vascular devices, S13
Thromboembolism, after IV immunoglobulin infusion, 265
Thyroid-stimulating hormone, deficiency/excess of, 36
Transfusions, universal leukocyte reduction for, 273
U
Ultrasound guidance, for central venous catheter placement, S7
Universal leukocyte reduction, 273
Uveitis, in juvenile idiopathic arthritis, 385
V
Vascular access devices. See also Catheter(s)
diagnostic tools and therapeutic interventions affecting, S13
epidural, 377
innovations in, S7
intrathecal, 377
legal aspects of, S18
patients' experience with, 61
Vasopressin, deficiency/excess of, 36
Viral hepatitis, liver function tests in, 108
Viral meningitis, after IV immunoglobulin infusion, 265
Vision loss, in juvenile idiopathic arthritis, 385
W
Withdrawal symptoms, in neonates, 159